| 1 |
Alho A, Santos NF, Felício R, Vieira CJ. Anti-Leucine-Rich Glioma-Inactivated 1 (Anti-LGI 1) Limbic Encephalitis and New-Onset Psychosis: A Case Report. Cureus 2023. [DOI: 10.7759/cureus.36223] [Reference Citation Analysis]
|
| 2 |
Liu X, Li G, Yu T, Lv R, Cui T, Hogan RE, Wang Q. Prognostic significance and extra-hypothalamus dysfunction of hyponatremia in anti-leucine-rich glioma-inactivated protein 1 encephalitis. J Neuroimmunol 2022;373:578000. [PMID: 36410057 DOI: 10.1016/j.jneuroim.2022.578000] [Reference Citation Analysis]
|
| 3 |
Mueller C, Elben S, Day GS, Alves P, Hebert J, Tang-Wai DF, Holtmann O, Iorio R, Perani D, Titulaer MJ, Hansen N, Bartsch T, Johnen A, Illes Z, Borm L, Willison AG, Wiendl H, Meuth SG, Kovac S, Bölte J, Melzer N. Review and meta-analysis of neuropsychological findings in autoimmune limbic encephalitis with autoantibodies against LGI1, CASPR2, and GAD65 and their response to immunotherapy. Clin Neurol Neurosurg 2022;224:107559. [PMID: 36549220 DOI: 10.1016/j.clineuro.2022.107559] [Reference Citation Analysis]
|
| 4 |
Du Y, Zhao C, Liu J, Li C, Yan Q, Li L, Hao Y, Yao D, Si H, Zhao Y, Zhang W. Simplified regimen of combined low-dose rituximab for autoimmune encephalitis with neuronal surface antibodies. J Neuroinflammation 2022;19:259. [PMID: 36273158 DOI: 10.1186/s12974-022-02622-8] [Reference Citation Analysis]
|
| 5 |
Papiri G, Puca E, Marcucci M, Paci C, Cagnetti C. A Case of Anti-Leucine-Rich Glioma-Inactivated Protein 1 (Anti-LGI1) Encephalitis With an Unusual Frontomesial Motor Cortex T2 MRI Hyperintensity. Cureus 2022. [DOI: 10.7759/cureus.30480] [Reference Citation Analysis]
|
| 6 |
Hang H, Lin L, Li D, Li J, Shi J, Lu J. Association between clinical factors and orofacial dyskinesias in anti-N-methyl-D-aspartate receptor encephalitis. Brain Behav 2022;12:e2638. [PMID: 35620876 DOI: 10.1002/brb3.2638] [Reference Citation Analysis]
|
| 7 |
Liu Z, Li Y, Wang Y, Zhang H, Lian Y, Cheng X. The Neutrophil-to-Lymphocyte and Monocyte-to-Lymphocyte Ratios Are Independently Associated With the Severity of Autoimmune Encephalitis. Front Immunol 2022;13:911779. [DOI: 10.3389/fimmu.2022.911779] [Reference Citation Analysis]
|
| 8 |
Li G, Liu X, Wang M, Yu T, Ren J, Wang Q. Predicting the functional outcomes of anti-LGI1 encephalitis using a random forest model. Acta Neurol Scand 2022. [PMID: 35373330 DOI: 10.1111/ane.13619] [Reference Citation Analysis]
|
| 9 |
Cui LL, Boltze J, Zhang Y. Positive LGI1 Antibodies in CSF and Relapse Relate to Worse Outcome in Anti-LGI1 Encephalitis. Front Immunol 2021;12:772096. [PMID: 34975858 DOI: 10.3389/fimmu.2021.772096] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 10 |
Baudin P, Cousyn L, Navarro V. The LGI1 protein: molecular structure, physiological functions and disruption-related seizures. Cell Mol Life Sci 2021;79:16. [PMID: 34967933 DOI: 10.1007/s00018-021-04088-y] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 11 |
Seifert-Held T, Eberhard K, Lechner C, Macher S, Hegen H, Moser T, Jacob GB, Puttinger G, Topakian R, Guger M, Kacar E, Zoche L, De Simoni D, Seiser A, Oberndorfer S, Baumgartner C, Struhal W, Zimprich F, Sellner J, Deisenhammer F, Enzinger C, Reindl M, Rauschka H, Berger T, Höftberger R. Functional Recovery in Autoimmune Encephalitis: A Prospective Observational Study. Front Immunol 2021;12:641106. [PMID: 34093529 DOI: 10.3389/fimmu.2021.641106] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
